Axonics takes on Medtronic, neuromodulation implant gets CE mark

Axonics SNM System--Courtesy of Axonics

Barely 6 months after raising a $38.5 million Series B to advance its neuromodulation implant to treat overactive bladder and fecal dysfunction, Axonics Modulation Technologies won a CE mark for the device.

In addition to the EU marketing approval, Irvine, CA-based Axonics has also received approval from some centers in Western Europe to start a 65-patient postmarket clinical follow-up (PMCF) study, Axonics said in a statement. According to, the University College London Hospital in the U.K. will host one of these studies, but has yet to start recruiting. Axonics did not disclose plans for U.S. trials.

The Sacral Neuromodulation System (SNM) implant is comprised of a four-electrode-tined lead, a remote control, a wireless charging system and a dedicated touchscreen tablet for lead placement and programming. It is 60% smaller than Medtronic's ($MDT) FDA- approved InterStim SNM implant, which is intended to increase patient comfort. It is also the first rechargeable implant for this indication and has a 15-year life span, said to be three times longer than Medtronic's device.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

While the device can spare patients from additional procedures to replace the device, it also reduces costs for the U.S. healthcare system by as much as $12 billion over the next 15 years, Axonics said in the statement. Currently, patients with non-rechargeable devices require replacements, and therefore surgeries, every four to 5 years, Dr. Karen Noblett of the UC Riverside School of Medicine said in the statement

An estimated 85 million adults in the U.S. and Europe suffer from an overactive bladder, while another 40 million are affected by fecal incontinence. More than 200,000 patients have undergone SNM therapy in the U.S. and Europe, and the therapy has proven superior to standard drug treatments. With its durability and size advantages, the company hopes Axonics' implant has the potential to challenge Medtronic's domination in the space.

- read the release

Suggested Articles

Bayer led One Drop’s $40 million series B round and licensed its technology for its “bio-digital efforts” in areas such as cancer and heart disease.

Abbott has received European approvals for two devices designed for children and infants with life-threatening heart defects.

Using ultra-small implants being developed by Iota Biosciences, Astellas Pharma hopes to explore new methods of delivering diagnostics and therapies.